Phlow Corp. Announces Formation of Business Advisory Board,

RICHMOND, Va., Feb. 02, 2023 (GLOBE NEWSWIRE) — Phlow Corp., a US-based not-for-profit company that leverages advanced manufacturing processes to power the domestic production of pharmaceutical products critical to the US healthcare system. to reshape, today announced the formation of the Phlow Business Advisory Board, comprised of internationally recognized leaders in the pharmaceutical, biotechnology and healthcare sectors who bring a wealth of knowledge and industry experience to the company; the addition of Melinda Hancock of Sentara Health System to Phlow’s Board of Directors; and the promotion of Dan Hackman from chief business officer to president.

The Phlow Business Advisory Board (PBAB) – whose experience spans pharmaceutical contract development and manufacturing, healthcare technology and data, and capital markets – will work closely with Phlow’s internal leadership to address issues related to growth and transformation opportunities of the company. Comprised of highly respected leaders, the PBAB reflects Phlow’s commitment to leverage decades of hands-on experience and diversity of thought to drive future growth as the company works to fulfill its mission to bring affordable, high quality, and essential medicines reliably to the people Supply USA -based advanced manufacturing processes. Members appointed to the PBAB include:

• Salvatore Guccione, Managing Director of Vasto Advisors. Former Chairman of The Emmes Company, LLC. Board Member and Chairman of the Strategy and M&A Committee of the Board of Directors of The Emmes Company, Chairman of Resolve Surgical Technologies and Vice Chairman of Allentown, Inc.

• Steven Klosk, former CEO of Cambrex, Senior Director of the Board of Formulated Solutions, Board Member of NJ Bio, Recipharm, BIOVECTRA, BioIVT and Lisata Therapeutics.

• Tim M. Mayleben, president of two private biopharmaceutical companies and board member of Marinus Pharma and Landos Biopharma. Previously longtime CEO of Esperion and board member of LOXO, Vericel and a number of other public and private biopharmaceutical companies.

• Joe Smith, Chief Scientific Officer at BD, Fellow at AIMBE, Adjunct Associate Professor at Johns Hopkins University and Advisory Board Member at Johns Hopkins University, Department of Biomedical Engineering.

• Guy Villax, former CEO and current board member at Hovione, former chairman of Rx360, former board member of European Fine Chemicals Group and current board member of EIT HealtC.

• Joseph Warchol, Chief Financial Officer North America at Curium Pharma and former Chief Financial Officer at SK pharmteco.

“A bold new approach is needed in the United States to completely redesign our critical life-changing drug supply chain from start to finish,” Edwards said. “I am pleased to announce the formation of the Phlow Business Advisory Board. The experience and insights this group brings to the Company will be invaluable as we move toward our next phase of growth and unlock transformational opportunities to solve some of our country’s most critical access challenges to life-saving essential medicines. I am honored and honored to have the support of these renowned advisors as we work together to ensure Phlow’s mission is fully realized.”

Melinda Hancock is currently Executive Vice President and Chief Administrative Officer of Sentara Health System and a member and past national chair of the Healthcare Financial Management Association. “We are excited that Melinda’s expertise, healthcare experience and financial acumen will support Phlow’s next phase of growth,” commented Eric Edwards, MD, PhD, co-founder and Chief Executive Officer of Phlow. “Your commitment to Phlow’s mission and vision, as well as to the needs of our healthcare partners as we work together to solve drug shortages, will greatly complement the current experience of Phlow’s Board of Directors.”

Since first joining Phlow in 2020, Dan Hackman has had a relentless focus on building great teams, nurturing a culture of success and driving great business, managerial and operational results. As a result, and to foster excellence in execution and accelerate growth, Hackman was promoted from chief business officer to president, with Edwards remaining CEO. He has held leadership positions at Kaleo, LivaNova and Guidant/Boston Scientific. “I look forward to taking on this new role at Phlow and look forward to working with our world-class teams to secure our nation’s supply chain for important pharmaceuticals and serve our commercial customers,” said Hackman of his promotion to president.

About Phlow

Phlow Corp. is a US-based not-for-profit company that uses advanced manufacturing technologies to transform the domestic production of essential starting materials (CSM), active pharmaceutical ingredients (API) and finished pharmaceutical products critical to the US healthcare system. Focused on impact, Phlow works with children’s hospitals, the private sector and the US government to improve access to affordable, high-quality essential medicines through end-to-end solutions that are fully integrated, comprehensive and greener. Leveraging its advanced R&D labs and world class, automated API cGMP capabilities at kilo to ton scale, Phlow offers custom contract development and

Manufacturing services for small molecule APIs and KSMs for pharmaceutical and biotechnology companies. Phlow measures its success by its ability to reduce cost and waste, improve quality and yield, and offer a greener approach to pharmaceutical manufacturing that leads to healthy and resilient communities. Visit www.phlow-usa.com for more information.

###